Title | Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. |
Publication Type | Journal Article |
Year of Publication | 2015 |
Authors | Ince TA, Sousa AD, Jones MA, J Harrell C, Agoston ES, Krohn M, Selfors LM, Liu W, Chen K, Yong M, Buchwald P, Wang B, Hale KS, Cohick E, Sergent P, Witt A, Kozhekbaeva Z, Gao S, Agoston AT, Merritt MA, Foster R, Rueda BR, Crum CP, Brugge JS, Mills GB |
Journal | Nat Commun |
Volume | 6 |
Pagination | 7419 |
Date Published | 2015 Jun 17 |
ISSN | 2041-1723 |
Keywords | Carcinoma, Cell Line, Tumor, Cisplatin, Culture Media, Drug Screening Assays, Antitumor, Female, Gene Expression Profiling, Heterografts, Humans, Ovarian Neoplasms, Paclitaxel, Phenotype |
Abstract | Currently available human tumour cell line panels consist of a small number of lines in each lineage that generally fail to retain the phenotype of the original patient tumour. Here we develop a cell culture medium that enables us to routinely establish cell lines from diverse subtypes of human ovarian cancers with >95% efficiency. Importantly, the 25 new ovarian tumour cell lines described here retain the genomic landscape, histopathology and molecular features of the original tumours. Furthermore, the molecular profile and drug response of these cell lines correlate with distinct groups of primary tumours with different outcomes. Thus, tumour cell lines derived using this methodology represent a significantly improved platform to study human tumour pathophysiology and response to therapy. |
DOI | 10.1038/ncomms8419 |
Alternate Journal | Nat Commun |
PubMed ID | 26080861 |
PubMed Central ID | PMC4473807 |
Grant List | R01CA123219 / CA / NCI NIH HHS / United States P30 CA016672 / CA / NCI NIH HHS / United States R01-CA146445-01 / CA / NCI NIH HHS / United States R01 CA146445 / CA / NCI NIH HHS / United States R01 CA123219 / CA / NCI NIH HHS / United States U01 CA168394 / CA / NCI NIH HHS / United States P50 CA083639 / CA / NCI NIH HHS / United States |
Related Faculty:
Tan Ince, M.D., Ph.D.